Tags

Type your tag names separated by a space and hit enter

A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD.
Gastroenterol Res Pract 2016; 2016:7109270GR

Abstract

Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the western world with prevalence of 20-33%. NAFLD comprises a pathological spectrum. Nonalcoholic fatty liver (NAFL) is at one end and consists of simple hepatic steatosis. On the contrary, nonalcoholic steatohepatitis (NASH) consists of steatosis, inflammation, and ballooning degeneration and can progress to cirrhosis. Despite the rising incidence, definitive treatment for NAFLD, specifically NASH, has not yet been established. Lifestyle modification with dietary changes combined with regular aerobic exercise, along with multidisciplinary approach including cognitive behavior therapy, has been shown to be an effective therapeutic option, even without a significant weight loss. Pioglitazone and vitamin E have shown to be most effective in NASH patients. Surgery and weight loss medication are effective means of weight loss but can potentially worsen NASH related fibrosis. Other agents such as n-3 polyunsaturated fatty acids, probiotics, and pentoxifylline along with herbal agent such as milk thistle as well as daily intake of coffee have shown potential benefits, but further well organized studies are definitely warranted. This review focuses on the available evidence on pharmaceutical and nonpharmaceutical therapy in the treatment and the prevention of NAFLD, primarily NASH.

Authors+Show Affiliations

Department of Gastroenterology, New York Methodist Hospital, Brooklyn, NY 11215, USA.Department of Gastroenterology, New York Methodist Hospital, Brooklyn, NY 11215, USA.Department of Gastroenterology, New York Methodist Hospital, Brooklyn, NY 11215, USA.

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

27006654

Citation

Hossain, Newaz, et al. "A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD." Gastroenterology Research and Practice, vol. 2016, 2016, p. 7109270.
Hossain N, Kanwar P, Mohanty SR. A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterol Res Pract. 2016;2016:7109270.
Hossain, N., Kanwar, P., & Mohanty, S. R. (2016). A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterology Research and Practice, 2016, p. 7109270. doi:10.1155/2016/7109270.
Hossain N, Kanwar P, Mohanty SR. A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. Gastroenterol Res Pract. 2016;2016:7109270. PubMed PMID: 27006654.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD. AU - Hossain,Newaz, AU - Kanwar,Pushpjeet, AU - Mohanty,Smruti R, Y1 - 2016/02/23/ PY - 2015/10/15/received PY - 2016/01/27/accepted PY - 2016/3/24/entrez PY - 2016/3/24/pubmed PY - 2016/3/24/medline SP - 7109270 EP - 7109270 JF - Gastroenterology research and practice JO - Gastroenterol Res Pract VL - 2016 N2 - Nonalcoholic fatty liver disease (NAFLD) is the most common liver disease in the western world with prevalence of 20-33%. NAFLD comprises a pathological spectrum. Nonalcoholic fatty liver (NAFL) is at one end and consists of simple hepatic steatosis. On the contrary, nonalcoholic steatohepatitis (NASH) consists of steatosis, inflammation, and ballooning degeneration and can progress to cirrhosis. Despite the rising incidence, definitive treatment for NAFLD, specifically NASH, has not yet been established. Lifestyle modification with dietary changes combined with regular aerobic exercise, along with multidisciplinary approach including cognitive behavior therapy, has been shown to be an effective therapeutic option, even without a significant weight loss. Pioglitazone and vitamin E have shown to be most effective in NASH patients. Surgery and weight loss medication are effective means of weight loss but can potentially worsen NASH related fibrosis. Other agents such as n-3 polyunsaturated fatty acids, probiotics, and pentoxifylline along with herbal agent such as milk thistle as well as daily intake of coffee have shown potential benefits, but further well organized studies are definitely warranted. This review focuses on the available evidence on pharmaceutical and nonpharmaceutical therapy in the treatment and the prevention of NAFLD, primarily NASH. SN - 1687-6121 UR - https://www.unboundmedicine.com/medline/citation/27006654/full_citation L2 - https://dx.doi.org/10.1155/2016/7109270 DB - PRIME DP - Unbound Medicine ER -